Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling

NCT06717295 is registered in ClinicalTrials.gov with Javier Toledo as lead sponsor.

NCT NCT06717295
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06717295 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling
Lead sponsor
Javier Toledo
Phase
Observational
Overall status
Recruiting
Start date
December 20, 2025
Completion date
August 1, 2028
Enrollment
6,000 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

brest cancer, colorectal cancer, glioblastoma (gbm), liver carcinoma, lung cancer (nsclc), ovarian cancer, pancreatic cancer, adult, prostate cancers